MIAMI - Pasithea Therapeutics Corp. (NASDAQ: KTTA), a micro-cap biotech firm with a market capitalization of $2.63 million focusing on developing treatments for central nervous system disorders and ...

Researchers have conducted one of the largest eye studies in the world to reveal new insights into retinal thickness, highlighting its potential in the early detection of diseases like type 2 diabetes ...

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...